At Novo Nordisk, patient safety is a top priority.  As the sole manufacturer of FDA-approved medicines containing semaglutides, Novo Nordisk is deeply concerned by companies promoting and selling non-FDA-approved knock-off drugs that claim to contain the same “semaglutide.”  As a result of the concerning dynamics in the marketplace, Novo Nordisk is committed to raising awareness of the dangers of compounded or knock-off “semaglutide”.  Here are three important facts to know if you or someone you care for is considering an unapproved, compounded product.